Remove AFIB Remove Atrial Fibrillation Remove Strokes
article thumbnail

Stroke Survivors With Afib Could Start DOACs Earlier

Med Page Today

(MedPage Today) -- It was safe to start direct oral anticoagulant (DOAC) therapy without delay after acute ischemic stroke in people with atrial fibrillation (Afib), according to the OPTIMAS randomized trial. Stroke survivors randomized to early.

AFIB 115
article thumbnail

BRAIN-AF: Rivaroxaban Did Not Reduce Cognitive Decline, Stroke and TIA in Younger, Low-Risk Patients With AFib

American College of Cardiology

Rivaroxaban did not reduce the incidence of cognitive decline, stroke or transient ischemic attack (TIA) in patients younger than 65 with nonvalvular atrial fibrillation (AFib) and low risk for stroke, according to results from the BRAIN-AF trial.

AFIB 64
article thumbnail

Afib Detected After Stroke: Link to Recurrent Events Questioned

Med Page Today

(MedPage Today) -- Cryptogenic stroke survivors who went on to get an insertable cardiac monitor (ICM) had a similar risk of recurrent stroke whether or not any atrial fibrillation (Afib, AF) ever turned up on monitoring, an observational study.

AFIB 105
article thumbnail

Boston Scientific Bolsters AFib Mapping with Cortex Acquisition

CardiacWire

Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases.

AFIB 105
article thumbnail

Five facts about atrial fibrillation

Medical Xpress - Cardiology

Atrial fibrillation, or AFib, is a fast and irregular heart rhythm that, left untreated, can lead to blood clots, stroke and heart failure. It's the most common type of arrhythmia, a potentially serious condition in which the heart beats too quickly, too slowly or in an irregular pattern.

article thumbnail

Blood thinners didn’t reduce cognitive decline in adults 65 and younger with AFib

American Heart News - Heart News

Research Highlights: In the first large trial of its kind, the anti-clotting medication rivaroxaban did not lower the risk of cognitive decline, stroke or transient ischemic attack (TIA) in people younger than age 65 who had atrial fibrillation (AFib).

AFIB 52
article thumbnail

ENBALV: Edoxaban vs. Warfarin Following Bioprosthetic Valve Surgery in Patients With Non-Valvular AFib

American College of Cardiology

Edoxaban was comparable to warfarin in preventing stroke or systemic embolism and intracardiac thrombus in patients with non-valvular atrial fibrillation (AFib) within three months after bioprosthetic valve surgery, based on preliminary findings from the ENBALV trial presented at AHA 2024.

AFIB 55